InfuSystems Holdings Inc (INFU) (Q3 2026) Earnings Call Highlights: Record Revenue, Wound
InfuSystems Holdings Inc (INFU) reported Q3 2026 revenue growth of 3%, impacted by GE Healthcare contract restructuring. Device Solutions revenue declined, while Wound Care growth had lower margins. ERP implementation caused $5M in working capital pressure. Oncology business grew due to sales and workflow improvements. Q4 adjusted EBITDA margin guidance is 22-25%. The company expects continued growth in Oncology and Wound Care, with ERP benefits anticipated in 2027.
How this was made

The 30-second read
Why it matters
The clarified margin guidance narrows the valuation range, offering a modest trading edge.
Market read
Earnings call provides new guidance details that can influence INFU's short‑term price action.
What to watch
Potential upside from ERP efficiency gains in 2027 and continued oncology referral growth.
Background
InfuSystems reported Q3 2026 results with modest revenue growth and detailed Q4 margin guidance.
Ticker impact
Company disclosed adjusted EBITDA margin guidance for Q4 as a tighter range of 22%‑25% and clarified revenue growth constraints.
slight upside as investors price in tighter margin guidance range
The CFO's explicit range reduces uncertainty; no major operational change, so impact is limited.
Market effects
Device solutions and wound‑care segments face margin pressure, which may affect peers in medical device space.
U.S. healthcare equipment market sees modest pressure from contract restructuring.
Limited; primarily impacts InfuSystems and its immediate competitors.
Counterpoint
The guidance range may be overly optimistic given margin‑erosive new wound‑care business and ERP implementation costs.
Key entities
- ExecutiveBarry Steele
Chief Financial Officer who clarified margin guidance.
- ExecutiveCarrie Lachance
Chief Executive Officer who discussed oncology growth and wound‑care volume.



